FDA Approves AstraZeneca’s New Breast‑Cancer Therapy Amid Access Hurdles

Good news for many battling HER2‑low metastatic breast cancer: the FDA has officially approved AstraZeneca’s antibody‑drug conjugate, trastuzumab deruxtecan. The decision rests on the compelling results of the DESTINY‑Breast06 trial, which showed a notable bump in both progression‑free and overall survival compared with standard chemotherapy.

But, as with most breakthroughs, the story isn’t all smooth sailing. Insurers are already voicing concerns about the drug’s price tag—well north of $150,000 a year—and some patients worry that coverage delays could blunt the therapy’s impact. It’s a classic case of science racing ahead of the reimbursement playbook.

In related biotech headlines, Roivant Sciences has announced that its pulmonary hypertension candidate, RV‑324, met its primary endpoints in a Phase 2 study. The drug, which targets the endothelin pathway, trimmed the six‑minute walk distance decline by roughly 30% versus placebo, giving hope to a community that has long awaited novel options.

Elsewhere, the London‑based venture Moonwalk raised a fresh $120 million round to push forward its pipeline of longer‑acting obesity medicines. Investors seem eager for solutions that can stay effective without the frequent injections that have hampered earlier products.

All told, the biotech landscape remains a mix of celebration and caution. While regulatory wins like AstraZeneca’s offer tangible hope, the real‑world rollout—pricing, insurance, and patient access—will determine just how many lives are truly changed.